CCM clinches two accolades at 2018 Frost & Sullivan Malaysia Excellence Awards
KUALA LUMPUR: CCM Duopharma Biotech Bhd (CCM) recently received the ‘Pharmaceutical Company of the Year (Generics)’ and the ‘Halal Pharmaceutical Company of the Year’ awards at the 2018 Frost & Sullivan Malaysia Excellence Awards, acknowledging the company’s commitment to developing first-class products to address consumers’ health and well-being needs.
CCM’s latest achievements marked the Company’s third time getting the ‘Pharmaceutical Company of the Year (Generics)’ award and the second time receiving the ‘Halal Pharmaceutical Company of the Year’ at the Frost & Sullivan Malaysia Excellence Awards.
CCM Group managing director, Leonard Ariff Abdul Shatar said that they were delighted to have earned recognition from the prestigious Frost & Sullivan Malaysia Excellence Awards and dedicated the awards to CCM Duopharma’s hardworking employees who contributed to the success.
“We are truly honoured and humbled by our accomplishments and we could not have achieved the feat without the effort of our employees as well as the unwavering support of our consumers who put their trust in CCM Duopharma to meet their healthcare needs. The recognition has strengthened our commitment to continuously deliver high-quality pharmaceutical products to meet and exceed our consumers’ expectations,” said Leonard Ariff.
Leonard Ariff added that today’s consumers are taking advantage of the unlimited access to information, making them more demanding and discerning about their health.
“Consumers are more informed than ever and this has empowered them to take greater interest and accountability of their overall well-being. Hence, it is crucial for us to become more agile and constantly focus on innovation to improve consumer satisfaction.
“Being honoured with the two esteemed awards exemplifies CCM Duopharma’s dedication in advancing our goal of helping our consumers to lead healthier lives and catering to their increasing demand for Halal pharmaceutical products. We will continue to accelerate our effort in advocating the Halal concept in the pharmaceutical sector and add value to healthcare through our research and development initiatives,” Leonard Ariff added.
Rhenu Bhuller, partner & senior-vice president, Transformational Health, Asia Pacific at Frost & Sullivan commended CCM for its focus on best practices and a robust growth strategy that identifies unmet healthcare needs in Malaysia and the region.
“The Asean healthcare market is predicted to be worth US$137 billion in 2025 with opportunities for generic and halal pharmaceuticals and biosimilars due to the need for affordable care that meets the evolving needs of payors and consumers.
“With a vision to support healthcare needs not just today but for the future, CCM is working to ensure that Malaysians and consumers in Asean can have access to quality, affordable and consumer-friendly products,” she said.
CCM is currently the largest current Good Manufacturing Practice(cGMP)-Pharmaceutical certified manufacturer in Malaysia with facilities in Bangi, Klang and Glenmarie.
This standard ensures all production activities in the plants are in line with the standards established by Malaysia’s Health Ministry’s cGMP and international standards.
The annual Frost & Sullivan Malaysia Excellence Awards celebrates companies that have shown distinction in various industries including healthcare, electronics, chemicals, energy, environment, automotive, information, communication and logistics.
CCM Duopharma was first recognised by Frost & Sullivan in 2013 when it received the ‘Pharmaceutical Company of the Year (Generics)’ award.